AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. EPRX
  4. [6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Filing content is currently unavailable.

Source:

Stock EPRX logo
Eupraxia Pharmac

NASDAQ:EPRX

EPRX Rankings

#4167 Ranked by Market Cap
N/A Ranked by Dividends

EPRX Latest News

Aug 12, 2025
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Jul 8, 2025
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Jun 2, 2025
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
May 7, 2025
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

EPRX Latest SEC Filings

Jul 8, 2025
[6-K] Eupraxia Pharmaceuticals Inc. Current Report (Foreign Issuer)

EPRX Stock Data

188.57M
28.97M
19.13%
6.2%
0.46%
Biotechnology
Healthcare
Canada
Victoria